Following this activity, participants should be able to: (1) Discuss the role of the multidisciplinary care team for treatment of muscle-invasive bladder cancer and how locoregional therapy may be used for bladder preservation approaches. (2) Describe new and emerging systemic therapy options for patients with metastatic urothelial bladder cancer and how patient and disease characteristics can guide therapy choice. (3) Review the results of recent clinical trials for treatment of bladder cancer and their potential impact on treatment.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/96096
- Start Date: 2024-11-26 06:00:00
- End Date: 2024-11-26 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AbbVie (Any division) - Amount: 0.0 - Is Kind Support: False Source: AstraZeneca (Any division) - Amount: 0.0 - Is Kind Support: False Source: Coherus BioSciences - Amount: 0.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 0.0 - Is Kind Support: False Source: Eisai, Inc. - Amount: 0.0 - Is Kind Support: False Source: Genentech (Any division) - Amount: 0.0 - Is Kind Support: False Source: GlaxoSmithKline - Amount: 0.0 - Is Kind Support: False Source: Janssen (Any division) - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 0.0 - Is Kind Support: False Source: Sanofi S.A. - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest